Carmoterol

Carmoterol

Clinical data
Other names	TA-2005; CHF-4226
Routes of administration	Inhalation
ATC code	None
Legal status
Legal status	Development terminated
Identifiers
IUPAC name 8-Hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]-1H-quinolin-2-one
CAS Number	147568-66-9
PubChem CID	63952
ChemSpider	57545 Y
UNII	9810NUL4D1
ChEMBL	ChEMBL1094785 Y
Chemical and physical data
Formula	C21H24N2O4
Molar mass	368.433 g·mol−1
3D model (JSmol)	Interactive image
SMILES C[C@H](CC1=CC=C(C=C1)OC)NC[C@@H](C2=C3C=CC(=O)NC3=C(C=C2)O)O
InChI InChI=1S/C21H24N2O4/c1-13(11-14-3-5-15(27-2)6-4-14)22-12-19(25)16-7-9-18(24)21-17(16)8-10-20(26)23-21/h3-10,13,19,22,24-25H,11-12H2,1-2H3,(H,23,26)/t13-,19+/m1/s1 Key:IHOXNOQMRZISPV-YJYMSZOUSA-N

Carmoterol (INN; development codes TA-2005 and CHF-4226) is a non-catechol experimental ultra-long-acting β adrenoreceptor agonist (ultra-LABA) that was in clinical trials before 2010 when it has been withdrawn from further development based on evidence that the compound does not possess a competitive profile.

Preliminary studies indicated duration of its effect exceeding 24 hours after inhalation of 3 μg. The pharmacologic profile of this medication included the fact its potency in isolated guinea pig trachea is greater than that of formoterol and salmeterol. It is over 100 times more selective for bronchial muscle than myocardial tissue.